Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot community-based testing and treatment for latent tuberculosis infection in South Vietnam
ACTRN12619001439134Phase 4Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rifampicin, isoniazid and rifapentine in latent tuberculosis infection (LTBI) (3 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Treatment completion at at least 80 percent of scheduled doses. Started Jun 2020; status: completed.
02
Drugs
rifampicinisoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ACTRN12619001439134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001439134.